ACYCLOVIR SODIUM


Trade Names	ACYCLOVIR ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE ACYCLOVIR SODIUM ZOVIRAX
Synonyms	Aciclovir sodium Acyclovir Acyclovir sodium Acyclovir sodium salt BW 248U BW 248U SODIUM BW-248U SODIUM BW-248U-SODIUM Sodium acyclovir Zovirax
Status
Molecule Category	Salt-form
UNII	927L42J563
Parent Compound:	ACYCLOVIR


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	RMLUKZWYIKEASN-UHFFFAOYSA-M
Smiles	Nc1nc([O-])c2ncn(COCCO)c2n1.[Na+]
InChI	InChI=1S/C8H11N5O3.Na/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14;/h3,14H,1-2,4H2,(H3,9,11,12,15);/q;+1/p-1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H10N5NaO3
Molecular Weight	247.19
AlogP	-0.92
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	4.0
Polar Surface Area	119.31
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	16.0

Metabolites Network

visNetwork

Bioactivity

Mechanism of Action	Action	Reference
Human herpesvirus 1 DNA polymerase inhibitor	INHIBITOR	FDA

Cross References

Resources	Reference
ChEMBL	CHEMBL1200380
FDA SRS	927L42J563
PubChem	23665721
SureChEMBL	SCHEMBL40722

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).